Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC)

By Blumenschein George  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1802-1811

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to “Work it Out”?

By  

Current Pharmaceutical Design, Vol. 20, Iss. 24, 2014-01 ,pp. : 3863-3874

Bentham Science Publishers

Access to resources Recommend Favorite

The Significance and Relationship between Mast Cells and Tumour Angiogenesis in Non-small Cell Lung Carcinoma

By Dundar E   Oner U   Peker B Cengiz   Metintas M   Isiksoy S   Ak G  

The Journal of International Medical Research, Vol. 36, Iss. 1, 2008-01 ,pp. : 88-95

Field House Publishing

Access to resources Recommend Favorite

The Hypomethylation Agent Bisdemethoxycurcumin Acts on the WIF-1 Promoter, Inhibits the Canonical Wnt Pathway and Induces Apoptosis in Human Non-Small-Cell Lung Cancer

By  

Current Cancer Drug Targets, Vol. 11, Iss. 9, 2011-11 ,pp. : 1098-1110

Bentham Science Publishers

Access to resources Recommend Favorite

Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (TRAIL) Apoptosis In Vitro but not In Vivo

By  

Letters in Drug Design & Discovery, Vol. 8, Iss. 9, 2011-11 ,pp. : 861-867

Bentham Science Publishers

Access to resources Recommend Favorite